FDA Grants Third Orphan Drug Designation to Biostar Pharma's Utidelone for Pancreatic Cancer Treatment
FDA Grants Orphan Drug Designation to Utidelone
Biostar Pharma, Inc., the U.S. subsidiary of Beijing Biostar Biopharmaceutical Co., Ltd., has recently achieved a significant milestone: the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for their drug, Utidelone, aimed at treating pancreatic cancer. This marks the third ODD for Utidelone, following earlier designations for metastatic breast cancer and gastric cancer.
Understanding the Challenge of Pancreatic Cancer
Pancreatic cancer is notorious for its aggressive nature and insidious symptoms, often diagnosed at advanced stages. Dubbed the
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.